ABSTRACT

SARS-CoV-2 exacerbated the risk of cardiovascular diseases (CVDs), threatening world health. Novel drug delivery systems (NDDS) incorporating herbal medicines have the potential to boost CVD therapy's efficacy. The key intent of this study was to utilize aqueous root extract of Glycyrrhiza glabra Linn as a green reducing and capping agent for the silver nanoparticles (AgNPs) fabrication, followed by their characterization, standardization, and assessment for cardioprotective activity. Stable AgNPs formation was achieved by mixing the aqueous root extract with 1mM silver nitrate (AgNO3) solution. SEM, TEM, and DLS showed spherical GGNPs with an average size of 20–50nm. The 430nm surface plasmon band was characteristic. EDAX (41.69% weight) and ICP-AES (324ug/ml) verified silver content. The synthesized AgNPs were standardized by validated HPLC method for the content of glycyrrhizic acid as the marker compound was found to be 2.44±0.105mg. In-vitro release study suggested GGNPs follows the diffusion and degradation mixed release pattern for the sustain and controlled release. Synthesized AgNPs were tested for cardio-protection utilizing the CAM assay. GGNPs concentration raised the number of branching arteries in chicken choriallontoic membrane by 33 ± 2 at 1mg/ml, while100mg/ml GG extract concentration increased it by 38 ± 2. This shows GGNPs are more pro- angiogenic. In H9C2 cell line toxicity studies, GGNPs had no toxicity after 24 hours. The aforementioned experimental data on metal nanomedicine derived from herbal sources offers valuable insights into the scientific foundation for the development of novel treatment therapies in cardiovascular diseases (CVDs). Keywords: Glycyrrhiza glabra Linn, green synthesis, silver-nanoparticles, Cardioprotective, pro angiogenesis
Publication date: 01/05/2025

https://ijbpas.com/pdf/2025/May/MS_IJBPAS_2025_9021.pdf

Download PDF
https://doi.org/10.31032/IJBPAS/2025/14.5.9021